SP140–RESIST pathway regulates interferon mRNA stability and antiviral immunity
Kristen C. Witt, Adam Dziulko, Joohyun An, Filip Pekovic, Audrey Cheng, Grace Y. Liu, Ophelia V. Lee, David J. Turner, Azra Lari, Moritz M. Gaidt, Roberto A. Chavez, Stefan A. Fattinger, Preethy Abraham, Harmandeep S Dhaliwal, Angus Y. Lee, Dmitri I. Kotov, Laurent Coscoy, Britt A. Glaunsinger, Eugene Valkov, Edward B. Chuong, Russell E. Vance
Abstract
Abstract Type I interferons are essential for antiviral immunity 1 but must be tightly regulated 2 . The conserved transcriptional repressor SP140 inhibits interferon-β ( Ifnb1 ) expression through an unknown mechanism 3,4 . Here we report that SP140 does not directly repress Ifnb1 transcription. Instead, SP140 negatively regulates Ifnb1 mRNA stability by directly repressing the expression of a previously uncharacterized regulator that we call RESIST (regulated stimulator of interferon via stabilization of transcript; previously annotated as annexin 2 receptor). RESIST promotes Ifnb1 mRNA stability by counteracting Ifnb1 mRNA destabilization mediated by the tristetraprolin (TTP) family of RNA-binding proteins and the CCR4–NOT deadenylase complex. SP140 localizes within punctate structures called nuclear bodies that have important roles in silencing DNA-virus gene expression in the nucleus 3 . Consistent with this observation, we find that SP140 inhibits replication of the gammaherpesvirus MHV68. The antiviral activity of SP140 is independent of its ability to regulate Ifnb1 . Our results establish dual antiviral and interferon regulatory functions for SP140. We propose that SP140 and RESIST participate in antiviral effector-triggered immunity 5,6 .